Navin Molecular inaugurated Phase-one of its new cGMP-4 facility at the NFIL Dewas unit, underscoring its ongoing expansion in specialty chemicals and contract development and manufacturing (CDMO) services. The milestone was celebrated on 4 September 2025 in the presence of the company’s European partner.
Leadership at the Ceremony
The inauguration was attended by Chairman Vishad P. Mafatlal, Managing Director Nitin Kulkarni, and senior leaders of Navin Fluorine International Ltd. The presence of the leadership team and global partner highlighted the strategic importance of the new facility.
State-of-the-Art Infrastructure
The cGMP-4 site has been described as state-of-the-art, designed to meet global benchmarks with advanced technologies and rigorous standards. It is expected to enhance the company’s capabilities in delivering innovative solutions to international partners.
Commitment to Quality and Growth
By adding the cGMP-4 facility, Navin Molecular strengthens its position as a reliable partner for contract manufacturing services. The investment reflects the company’s long-term commitment to innovation, quality, and value creation in the specialty chemicals sector.
Company Statement
As reported by PharmaSource, a company statement mentioned, “The inauguration of this state-of-the-art facility marks another significant step in our commitment to innovation, reliability, and world-class standards in specialty chemicals and CDMO services.”
